A Randomized Trial Of Varenicline For Smoking Cessation In Latin America, Africa And The Middle East

Bolliger, Chris T.; Issa, Jaqueline Schölz; Posadas-Valay, Rodolfo; Safwat, Tarek; Abreu, Paula; Correia, Eurico A.; Chopra, Pravin

doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2648

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 19 RCTs were identified for potential meta-analysis (Aubin et al 2008;Bolliger et al 2010;Fagerstrom et al 2010;Gonzales et al 2006;Jorenby et al 2006;Nakamura et al 2007;Niaura et al 2008;Nides et al 2006;Oncken et al 2006;Rigotti et al 2010;Tashkin et al 2011;Tsai et al 2007;Tsukahara et al 2010;Wang et al 2009;Williams et al 2007). However, nine trials were excluded from the meta-analysis for the following reasons: seven trials reported a follow-up time shorter than 12 months (Wang et al 2009;Tsai et al 2007;Tsukahara et al 2010;Fagerstrom et al 2010;Hays et al 2011;Smith et al 2011;Bolliger et al 2010), one trial focused on the effect of maintenance therapy with varenicline (Tonstad et al 2006), and another trial was still ongoing at the time of our analysis (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…However, nine trials were excluded from the meta-analysis for the following reasons: seven trials reported a follow-up time shorter than 12 months (Wang et al 2009;Tsai et al 2007;Tsukahara et al 2010;Fagerstrom et al 2010;Hays et al 2011;Smith et al 2011;Bolliger et al 2010), one trial focused on the effect of maintenance therapy with varenicline (Tonstad et al 2006), and another trial was still ongoing at the time of our analysis (Fig. 1) (Pfizer 2009).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials

Huang

Yang³

et al. 2012

J Public Health

View full text Add to dashboard Cite

Aim To evaluate the long-term efficacy and potential risk of psychiatric side effects of varenicline for smoking cessation compared with placebo or nicotine replacement therapy. Subject and methods Systematic search of electronic databases (MEDLINE, EMBASE, Cochrane Central Register, SCI) up to March 2011. Two reviewers independently determined the eligibility of randomized controlled trials comparing varenicline with placebo, or nicotine replacement therapy with follow-up of at least 12 months. Information was independently extracted by 2 reviewers.Results Ten trials involving 6,375 smokers were included in the meta-analysis. The pooled risk ratios (RR) for continuous abstinence was 2.83 (95% CI: 2.20-3.63) at 52 weeks for varenicline (1 mg, twice per day) versus placebo. Varenicline seemed to be more effective in smokers with chronic obstructive pulmonary disease (RR, 3.33) than smokers with cardiovascular diseases (RR, 2.64) or health smokers (RR, 2.52), non-Asian smokers than Asian smokers (2.98 vs. 1.94), elder smokers than younger smokers (2.87 vs. 2.52), female smokers than male smokers (2.98 vs. 1.94). The five predominant reported adverse events for varenicline compared to placebo were vomiting, nausea, abnormal dreams, constipation, and dysgeusia. There was no sufficient evidence that varenicline was associated with an increased risk of psychiatric side effects (RR, 1.45, 95% CI: 0.90-2.32). Conclusion Varenicline therapy compared with placebo is associated with a favorable effect on smoking cessation at the end of 52 weeks. However, the psychiatric adverse events related with varenicline should be further studied with larger qualified study. People with preexisting mental illnesses should be prudently treated with varenicline.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials

Huang

Yang³

et al. 2012

J Public Health

View full text Add to dashboard Cite

show abstract

“…On the other hand, upon comparison of our continuous abstinence rate with other studies that used pharmacological approaches for smoking cessation. In randomized placebo controlled trial to evaluate the efficacy and tolerability of varenicline in smokers from 11 countries, including Egypt, the continuous abstinence rate (CAR) from the 9 th to the 12 th week was notably higher with varenicline administration, compared to placebo (53.59% vs.18.69%; p< 0.0001) [29] .Furthermore, Bassiouny et al1998 [30], reported that the abstinence rate among smokers after using nicotine patches for nine weeks was 50.6%, 28% after six months and 25.8% at the end of the year. Upon evaluation of the impact of citrus lemon essential oil inhalation on tobacco craving, it revealed reduction in the craving intensity among aromatherapy inhalation device users.…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of a New Smoking Cessation Approach: An Intervention Study

Mohammed

Hashish

2022

Int J Health Sci Res

View full text Add to dashboard Cite

Objective: This study evaluated the effectiveness of a new non pharmacological approach for smoking cessation (COL approach), on a sample of Egyptian smokers. Methods: This study was conducted for 12 weeks on two groups of current smokers willing to quit. An interventional group of 23 current cigarette smokers received a new approach composed of the inter-personal counselling; ready-made meal composed of Avena sativa L seeds in addition to an aromatherapy inhaler device containing an essential oil. A control group of 25 current smokers received interpersonal counselling only, for 12 weeks were compared to the intervention group. Results: The continuous abstinence rate was significantly higher (47.8%) and failure rate was significantly lower (21.8%) among the intervention group at the end of week 12 in comparison to the control group (16.0% and 56.0% respectively; P-value=0.02).The intervention group revealed a significant decline in the mean values of the TCI grade than the control group. In conclusion, the tested approach was effective in increasing the continuous abstinence rate, decreasing the craving numbers, intensity and decreasing the nicotine withdrawal symptoms as compared to the control group. Conclusion: The tested new approach could be embedded as a treatment option within a comprehensive tobacco control strategy. Thus, it is not an alternative but could be complementary for other evidence based strategies Key words: Smoking cessation, Natural, Aromatherapy, and Oat

show abstract

“…To date varenicline is approved for marketing in 91 countries and has been prescribed to over 12 million smokers worldwide. The clinical efficacy, tolerability and safety of varenicline have been further established in a trial with one year of continuous treatment with 1 mg BID [40], and in several trials across ethnicities including smokers from Asia, Latin America, Africa and the Middle East [41][42][43][44].…”

Section: Clinical Efficacy Of Vareniclinementioning

confidence: 99%

Pharmacodynamic and pharmacokinetic profiles of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, a smoking cessation aid

Faessel

Rollema

2016

J Pediatr Biochem

View full text Add to dashboard Cite

This review describes the role of ?4?2 containing nicotinic acetylcholine receptors in the mesolimbic reward pathway in the neurobiology of nicotine addiction and discusses the rationale for targeting this receptor with partial agonists as novel smoking cessation agents. Varenicline is a ?4?2 nicotinic acetylcholine receptor partial agonist that is a smoking cessation aid with a dual mechanism of action: relief of craving and withdrawal symptoms, as well as attenuation of nicotine reinforcement. The pharmacological profile of varenicline is consistent with that of a potent and selective partial agonist at the target receptor, both in in vitro and in vivo neurochemical and behavioral models. Varenicline was nominated for full clinical development in 1997, and later approved in the US and Europe as a smoking cessation aid in 2006. The recommended dose of varenicline is 1 mg BID for 12 weeks after an initial titration week in adult smokers motivated to stop smoking. The pharmacokinetics of varenicline is linear and consistent regardless of smoking status, age, gender or ethnic background. Varenicline is largely eliminated unchanged in the urine, and consequently a dose adjustment is warranted for patients with severe renal insufficiency. Although varenicline is currently not approved for use in smokers under age 18, its pharmacokinetic and tolerability profile in adolescents appeared generally similar to adults. Several large clinical trials have consistently shown the efficacy, tolerability and safety of varenicline in various ethnic smoking populations and in adult smokers with co-morbid chronic pulmonary or cardiovascular disease. Additional clinical studies in special patient populations are currently ongoing.

show abstract

A Randomized Trial Of Varenicline For Smoking Cessation In Latin America, Africa And The Middle East

Cited by 4 publications

References 0 publications

Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials

Long-term efficacy and safety of varenicline for smoking cessation: a systematic review and meta-analysis of randomized controlled trials

Clinical Evaluation of a New Smoking Cessation Approach: An Intervention Study

Pharmacodynamic and pharmacokinetic profiles of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, a smoking cessation aid

Contact Info

Product

Resources

About